Crispr’s Car-T crunch time
The group could soon provide clarity on CTX112’s regulatory path.
Another false dawn for p53
Boehringer discontinues brigimadlin while others continue to struggle.
BeiGene bows out of TIGIT
AstraZeneca and GSK/iTeos's odysseys get a little lonelier still.
Lilly’s big Jaypirca test approaches
After failure of its second-line trial to show an OS benefit, the pressure is on in the front line.
Compass claims a pivotal win with tovecimig
A biliary tract cancer trial hits on response rate, but survival data will be key.
Aura bids to join the bladder cancer crowd
As the non-muscle invasive space is carved up, Aura tries to seize part of it.
AACR 2025 preview – a surge in dual-payload conjugates
At least 15 dual-payload ADCs will be discussed.
